All In Biotech

Drug Trial Radar · NCT01185821

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Mar 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Aug 30, 2010

Primary completion

Oct 10, 2016

Study completion Oct 10, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 56 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • BAF312Drug

    BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study.Time frame: Baseline up to approximately 5 years
  2. Number of Participants With Cardiac Conduction Abnormalities During the Titration Phase of the Study (Without Washout)Time frame: Baseline Extension up to day 10
  3. Number of Participants With Cardiac Conduction-IVCD Abnormality During the Titration Phase of the Study (With Washout)Time frame: Baseline Extension up to day 10
  4. Number of Participants With Changes in Blood Pressure for Overall Extension Study. (Extension Analysis Set)Time frame: Baseline Extension up to approximately 5 years
  5. Number of Participants With Viral Infections of Interest Greater or Equal to 5% in Any Dose Group (Extension Set)Time frame: Baseline Extension up to approximately 5 years
  6. Number of Participants With Dermatologic Alterations - Basal Cell Carcinoma (Extension Set)Time frame: Baseline Extension up to approximately 5 years

Locations

46 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Pompano Beach, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Grand Rapids, Michigan

  • Novartis Investigative Site

    Akron, Ohio

  • Novartis Investigative Site

    Greenville, South Carolina

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Gatineau, Quebec, Canada

  • Novartis Investigative Site

    Greenfield Park, Quebec, Canada

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Tampere, Finland

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Ibbenbueren, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hungary

  • Novartis Investigative Site

    Veszprém, Hungary

  • Novartis Investigative Site

    Montichiari, BS, Italy

  • Novartis Investigative Site

    Chieti, CH, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Bergen, Norway

  • Novartis Investigative Site

    Oslo, Norway

  • Novartis Investigative Site

    Lodz, Poland

  • Novartis Investigative Site

    Lublin, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Kazan', Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Basel, Switzerland

  • Novartis Investigative Site

    Lugano, Switzerland

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.